Lenskart Solutions Private Limited operates as a prominent online eyewear retailer in India, offering a wide range of products including prescription glasses, sunglasses, and contact lenses for men, women, and children. Established in 2008 and based in New Delhi, the company has expanded its presence through numerous retail stores across various cities in India. Lenskart is known for its user-friendly online platform, where customers can select from over 500 designs of eye frames and enjoy features like 48-hour free home delivery and a 365-day return policy. The company provides an extensive selection of contact lenses from leading brands, catering to diverse customer needs. Additionally, Lenskart offers home eye check-up services in several major cities, enhancing customer convenience and accessibility to eye care.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.
HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other serious age-related conditions. The company specializes in precision pharmaceuticals, creating innovative genetic treatments that are selectively targeted to specific tissues and cells. HAYA Therapeutics employs a discovery engine that identifies tissue- and cell-specific drivers of fibrosis and other disease processes by leveraging non-coding RNAs in the human genome. Through its biopharmaceutical therapies, HAYA Therapeutics seeks to block myocardial fibrosis, offering potential new options for the management of heart failure and related disorders.
Bizongo is an online B2B marketplace focused on the packaging and material handling industries, offering solutions for packaging sourcing, distribution, inventory management, and design. Established in 2015 and headquartered in Mumbai, India, the company operates an automated supply chain platform that facilitates efficient inventory management while minimizing issues such as stockouts and excess inventory. Bizongo's vendor digitization platform enhances supply chain operations for made-to-order products, providing services such as digital vendor management, supply chain automation, and financing. By streamlining these processes, Bizongo helps businesses optimize their operations and reduce costs.
LEAP India Private Limited, founded in 2013 and based in Mumbai, specializes in the sale and rental of pallets and foldable large containers. The company provides a range of products including wooden pallets, plastic containers, wooden boxes, and metal wire mesh, catering to various industries such as fast-moving consumer goods, retail, beverage, and automobile. LEAP India also offers transportation services for product movement, inventory management, asset reconditioning, and an online pallet management tool that allows customers to place orders, track deliveries, view invoices, and generate reports. By focusing on efficient asset management and logistical solutions, LEAP India aims to support its clients in overcoming supply chain challenges and enhancing operational efficiency.
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.
Tessian Limited is a provider of an advanced email security platform that addresses human error in data handling, significantly reducing the risk of data loss. The platform employs machine learning and artificial intelligence to identify when emails are mistakenly sent to unintended recipients, alerting the sender in real time to allow corrections. It features tools such as CheckRecipient Guardian and CheckRecipient RuleBuilder, which enhance organizational control over email communications. Tessian’s technology is designed to analyze email networks and prevent the transmission of sensitive information to the wrong individuals, thereby safeguarding against threats like data exfiltration, business email compromise, and phishing attacks. The company serves various sectors, including legal services, healthcare, investment management, and technology. Founded in 2013 and headquartered in London, Tessian also has an office in San Francisco and is supported by prominent investors.
HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other serious age-related conditions. The company specializes in precision pharmaceuticals, creating innovative genetic treatments that are selectively targeted to specific tissues and cells. HAYA Therapeutics employs a discovery engine that identifies tissue- and cell-specific drivers of fibrosis and other disease processes by leveraging non-coding RNAs in the human genome. Through its biopharmaceutical therapies, HAYA Therapeutics seeks to block myocardial fibrosis, offering potential new options for the management of heart failure and related disorders.
Bizongo is an online B2B marketplace focused on the packaging and material handling industries, offering solutions for packaging sourcing, distribution, inventory management, and design. Established in 2015 and headquartered in Mumbai, India, the company operates an automated supply chain platform that facilitates efficient inventory management while minimizing issues such as stockouts and excess inventory. Bizongo's vendor digitization platform enhances supply chain operations for made-to-order products, providing services such as digital vendor management, supply chain automation, and financing. By streamlining these processes, Bizongo helps businesses optimize their operations and reduce costs.
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.
Memo Therapeutics AG, based in Basel, Switzerland, specializes in antibody discovery and immune repertoire analysis through its innovative MemoMAB platform. This technology enables the creation of a recombinant in vitro copy of an individual’s B cell and antibody repertoire, resulting in unique and extensive libraries that reflect a person's immune response. These libraries are anticipated to contain a significant number of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics employs its MemoMAB platform in proprietary antibody lead discovery programs and offers it for collaboration with other entities, enhancing the potential for novel therapeutic developments.
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.
Cedilla Therapeutics, Inc. is focused on developing targeted small-molecule medicines aimed at treating cancer and other diseases resulting from protein dysregulation. The company leverages unique insights into protein stability to create innovative therapeutic approaches, including direct ligand-induced degradation, disruption of protein-protein interactions, and the identification of upstream regulators that influence protein stability. Cedilla’s technology allows for the mapping of protein susceptibility to enhance endogenous degradation pathways, facilitating the transition from stable to susceptible protein states. Founded in 2018 and headquartered in Cambridge, Massachusetts, Cedilla Therapeutics aims to broaden the applicability of its therapies beyond oncology, addressing a range of conditions associated with protein dysregulation.
Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
Goldfinch Bio, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing precision therapies for kidney diseases. The company focuses on researching and commercializing treatments for conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Notable programs include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio is also developing the Kidney Genome Atlas, a genomic registry aimed at identifying new disease targets and biomarkers, and utilizes a biology platform that leverages stem cell science to create human organoid models for target validation. Founded in 2016 and based in Cambridge, Massachusetts, Goldfinch Bio has established a strategic collaboration with Gilead Sciences to enhance its capabilities in kidney disease therapy development.
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of therapies for fibrotic diseases. The company's lead candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, currently being developed for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both conditions and is undergoing Phase 2a trials for IPF, with plans for a Phase 2a trial in PSC. Pliant is also advancing PLN-1474, a small-molecule selective inhibitor of avß1, aimed at treating liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 clinical trials and has a partnership with Novartis. In addition to these clinical efforts, Pliant has two preclinical programs targeting oncology and muscular dystrophies. Founded in 2015, Pliant Therapeutics is committed to addressing unmet medical needs in the field of fibrosis.
Bizongo is an online B2B marketplace focused on the packaging and material handling industries, offering solutions for packaging sourcing, distribution, inventory management, and design. Established in 2015 and headquartered in Mumbai, India, the company operates an automated supply chain platform that facilitates efficient inventory management while minimizing issues such as stockouts and excess inventory. Bizongo's vendor digitization platform enhances supply chain operations for made-to-order products, providing services such as digital vendor management, supply chain automation, and financing. By streamlining these processes, Bizongo helps businesses optimize their operations and reduce costs.
iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.
ECheng (e成) is a B2B SaaS platform that provides HR matching and resume screening for enterprises. Using machine learning, data mining, and NLP (natural language processing), the company categorizes resumes that best fit the job requirements of the client company. The company was launched in 2013 by industry veterans from Baidu, IBM, and Microsoft, serving multinational conglomerates as well as small and medium-sized companies.
Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of therapies for fibrotic diseases. The company's lead candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, currently being developed for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both conditions and is undergoing Phase 2a trials for IPF, with plans for a Phase 2a trial in PSC. Pliant is also advancing PLN-1474, a small-molecule selective inhibitor of avß1, aimed at treating liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 clinical trials and has a partnership with Novartis. In addition to these clinical efforts, Pliant has two preclinical programs targeting oncology and muscular dystrophies. Founded in 2015, Pliant Therapeutics is committed to addressing unmet medical needs in the field of fibrosis.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.
Memo Therapeutics AG, based in Basel, Switzerland, specializes in antibody discovery and immune repertoire analysis through its innovative MemoMAB platform. This technology enables the creation of a recombinant in vitro copy of an individual’s B cell and antibody repertoire, resulting in unique and extensive libraries that reflect a person's immune response. These libraries are anticipated to contain a significant number of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics employs its MemoMAB platform in proprietary antibody lead discovery programs and offers it for collaboration with other entities, enhancing the potential for novel therapeutic developments.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Rethink Robotics is a company based in Boston, Massachusetts, focused on developing advanced robotic solutions for the manufacturing industry. Its flagship product, the Baxter robot, utilizes the Intera software platform to enhance workforce efficiency by integrating trainable, safe, and cost-effective robots alongside skilled human labor. Baxter is designed to automate repetitive and hazardous tasks, such as loading, packing, and inspection, thereby increasing flexibility and reducing operational costs for manufacturers in sectors like automotive, electronics, and consumer goods. Additionally, Rethink Robotics offers the Baxter Research Robot for academic and corporate research, featuring integrated sensors and an open software development kit for custom application development. The company's mission is to drive innovation in robotics and support manufacturers in adapting to the demands of an agile economy. Rethink Robotics is backed by prominent investors, including Bezos Expeditions and Charles River Ventures.
Aevi International GmbH is a technology company based in Paderborn, Germany, that specializes in creating an open ecosystem for payment solutions. Founded in 2015, Aevi develops the Digital Service Center, a vendor-agnostic platform that allows merchant solution providers to select and customize applications, payment services, and compatible devices to enhance their digital strategies. The company serves various sectors, including retail, hospitality, postal services, and financial services, enabling providers to transition from traditional payment methods to a more versatile environment that integrates apps and smart devices. By facilitating a collaborative ecosystem among merchant solution providers, app developers, and device vendors, Aevi simplifies the payment landscape, offering a single integration point and fostering flexibility and choice. This approach not only streamlines operations but also supports the acquisition of new merchants, customer retention, cost savings, and the development of new revenue streams. Aevi operates internationally, with additional offices in the United Kingdom and the Czech Republic, and is a subsidiary of Wincor Nixdorf International GmbH.
FirstCry is an online platform specializing in baby and children's products, offering over 20,000 items from more than 250 renowned international and Indian brands, including Mattel, Pigeon, Pampers, and Disney. Founded in 2010 and headquartered in Pune, India, the company focuses on providing a high-quality online shopping experience with competitive pricing, efficient delivery services, and responsive customer support. In addition to its retail operations, FirstCry is involved in the wholesale sector, promoting and selling baby products and fast-moving consumer goods through various business partners. The company also operates a preschool segment via franchise partnerships across India.
Lenskart Solutions Private Limited operates as a prominent online eyewear retailer in India, offering a wide range of products including prescription glasses, sunglasses, and contact lenses for men, women, and children. Established in 2008 and based in New Delhi, the company has expanded its presence through numerous retail stores across various cities in India. Lenskart is known for its user-friendly online platform, where customers can select from over 500 designs of eye frames and enjoy features like 48-hour free home delivery and a 365-day return policy. The company provides an extensive selection of contact lenses from leading brands, catering to diverse customer needs. Additionally, Lenskart offers home eye check-up services in several major cities, enhancing customer convenience and accessibility to eye care.
Private Equity Round in 2014
Airborne International is engaged in engineering, manufacturing, and supplying high-end composites structures for industries such as aerospace, defense, marine, high-end bicycles, and formula-one cars. It offers composites structures maintenance and repair services, including inspection and damage assessment, sealing and painting, and balancing. The company was founded in 1995 and is based in The Hague, the Netherlands.
Private Equity Round in 2013
Secured Mail, established in 2006 by Mark Bigley, operates as a licensed postal service provider in the United Kingdom. It has rapidly become a significant player in the wholesale Downstream Access (DSA) market, ranking third. The company collects mail directly from customers' production facilities and utilizes its own fleet to transport and sort this mail at its hubs before delivering it nationwide. Secured Mail partners with Royal Mail to ensure that mail is delivered to recipients the day after collection, completing the delivery process known as 'the Final Mile.' Its diverse client base includes prominent companies such as Amazon, Domino's Pizza, and Centrica, which owns British Gas.